若生智能
Drug Database
PT

PT-003

✓ Approved

Pediatrix Therapeutics · 未知 · 未知

什么是 PT-003？

PT-003 是一种未知，由Pediatrix Therapeutics研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

公司Pediatrix Therapeutics
药物类别未知
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, Pediatrix Therapeutics

治疗适应症

PT-003 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Immune system disordersHypersensitivity✓ Approved

相关研究文献

PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-08-04

Reconfiguration of Localized Ruthenium Surface via Incorporating Single Platinum Atoms for Favorable Hydrogen Oxidation Catalysis.

Choi Daeil D, Lee Dong Wook DW, Song Hochang H, Kim Seung-Hoon SH et al.

Despite the fact that only 2% of active sites can satisfy hydrogen oxidation reaction (HOR) activity thanks to fast kinetics, the fuel cell anode is still dependent on catalysts with large amounts of platinum (Pt). Herein, a minimal-cost ruthenium catalyst bearing ultralow quantities of Pt single atoms (RuPtSA) is developed to provide a high catalytic activity and tolerance to impurities as well as breakthrough reduction in Pt loading amounts. By introducing 1 wt.% Pt as a galvanic replacement for the Ru lattice, the active sites for the adsorption/desorption of hydrogen and CO are redefined. Ru acts both as an electron donor to Pt and as a host for OH groups, thereby accelerating the catalytic process. Using 1 wt.% Pt atoms, the HOR activity and CO resistance of Ru/C are improved, and the HOR mass activity of RuPtSA/C is 25.4-fold higher than that of Pt/C. Synergy between Ru and Pt is demonstrated by density functional theory calculations and verified using practical single-cell evaluations. Furthermore, RuPtSA/C exhibits an 18.4-fold higher mass activity than Pt/C in the HOR of an anion exchange membrane fuel cell, indicating its promise for use as a universal fuel cell anode catalyst.

PMID 42549631
阅读全文 →
PubMedMikrochimica acta2026-08-04

Pt nanoparticles-engineered metal-organic framework encapsulated by a covalent organic framework shell for self-powered photoelectrochemical sensing of carbendazim.

Qin Peng P, Teng Yan Y, Zeng Yue Y, Qin Lu L et al.

To address the food safety risks caused by carbendazim (CBZ) residues, a high-efficiency self-powered photoelectrochemical (PEC) sensing platform was constructed for sensitive detection of CBZ. We present a PEC sensing interface based on a Pt nanoparticles-engineered ZIF-8 core encapsulated by a covalent organic framework (COF) shell (Pt NPs-ZIF-8@COF). Distinct Pt integration pathways were evaluated, revealing that in situ encapsulation of Pt NPs during ZIF-8 crystallization (Pt NPs-ZIF-8) mitigates particle aggregation and outperforms post-synthetic decoration of Pt NPs onto post-synthetic ZIF-8 (Pt NPs/ZIF-8). The COF overlayer further tailors the interfacial microenvironment by establishing a continuous charge-transport network, which together accelerate photogenerated charge separation and interfacial electron-transfer processes. Benefiting from these synergistic features, the resulting PEC sensor enables quantitative CBZ determination over a wide linear range from 1.0 × 10- 8 to 1.0 × 10- 2 µg/mL, with an ultralow detection limit of 3.3 × 10- 9 µg/mL. This work underscores a modular nanoparticles-in-MOF plus COF encapsulation strategy for building high-performance PEC biosensing interfaces and offers a promising route toward rapid pesticide-residue monitoring.

PMID 42550303
阅读全文 →
PubMedInternational journal of sports physical therapy2026-08-04

Defining the Minimal Clinically Important Difference (MCID), Patient Acceptable Symptom State (PASS), and Maximal Outcome Improvement (MOI) values for individuals with acetabular dysplasia (AD) undergoing non-operative management.

Disantis Ashley E AE, Ellis Tom T, Kollmorgen Robert R, Luck Connor C et al.

The International Hip Outcome Tool 12 (iHOT-12) is commonly utilized to track outcomes in individuals with acetabular dysplasia (AD). Clinically important outcome values (CIOVs) of the iHOT-12 in individuals with AD are not yet defined. To define the minimal clinically important difference (MCID), patient acceptable symptom state (PASS) change score, absolute PASS threshold, and maximal outcome improvement (MOI) value for the iHOT-12 in individuals undergoing physiotherapy (PT) for AD. Prospective cohort; psychometric property analysis. This prospective study included individuals aged 10-35 years with a clinical and radiographic diagnosis of AD who were referred for conservative management at two centers between December 2023 and February 2025. At baseline assessment and after 8-10 weeks of PT, individuals completed the iHOT-12. At 8-10-week follow-up, individuals also completed three anchor questions on satisfaction and function. The MCID was calculated utilizing 0.5 times the standard deviation of baseline iHOT-12 scores. Receiver operator curve analysis was utilized to determine the PASS change score, absolute PASS threshold, and MOI value. Forty-five patients (42 females, mean age 16.5 + 7.8) met the inclusion criteria. After 8-10 weeks of PT (mean follow-up time = 69 days), 25 (55.6%) participants were in the "improved" group and 20 (44.4%) were in the "not improved" group. The MCID was 8.5 points. A PASS change score of 15.2 was calculated for individuals who were satisfied with high sensitivity (.77) and specificity (.78) with an AUC = .76 (95% CI: .59-.93). An absolute PASS iHOT-12 threshold score of 62 (sensitivity = .62, specificity = .87) identified those who were satisfied with their hip function after a trial of PT with an AUC = .82 (95% CI: .67-.97). An MOI threshold of 22.9% was also calculated with high sensitivity (.69) and specificity (.88) with an AUC = .78 (95% CI: .61-.95). This study defines MCID, PASS change score, absolute PASS threshold, and MOI threshold for the iHOT-12 in patients with AD after 8-10 weeks of PT. While most individuals reported improvement in symptoms, only half of individuals were satisfied with their current level of function. Level 2.

PMID 42549202
阅读全文 →
PubMedClinical therapeutics2026-08-04

Sex-Specific Safety Profiles of PI3K Inhibitors: A Real-World Pharmacovigilance Study Based on FAERS Database.

Zhang Ximin X, Lu Weitao W, Zou Dongyin D, He Caiping C et al.

This study aimed to investigate the sex-associated adverse events (AEs) reporting differences of phosphatidylinositol 3-kinase (PI3K) inhibitors from the US Food and Drug Administration Adverse Event Reporting System (FAERS), thereby providing a more solid foundation for evidence-based clinical practice. All PI3K inhibitors were searched as primary and secondary suspected drugs from FAERS data (January 2004 to July 2025). We performed disproportionality analyses using reporting odds ratios (ROR) to evaluate the associations between PI3K inhibitors and adverse events. Among the 6,209 AE reports associated with PI3K inhibitors, alpelisib exhibited a female predominance (82.7%), accompanied by a stronger hyperglycaemia signal in females (reporting odds ratio [ROR] 187.6 vs 79.3). Following false discovery rate (FDR) correction, significant sex differences at the preferred term (PT) level persisted for alpelisib (female predominance in hyperglycaemia, rash, and diarrhoea), yet no significant differences at the system organ class (SOC) level remained. Idelalisib demonstrated a male predominance (54.9%), with comparable diarrhoea signals between the sexes. Regarding copanlisib and duvelisib, the limited number of cases precluded reliable sex-specific comparisons. This research identifies sex-specific AE patterns for PI3K inhibitors. Subsequent to FDR correction, significant PT level sex differences were detected for alpelisib, yet not for idelalisib. Moreover, no differences at the standard of care SOC level persisted for either drug. The findings regarding copanlisib and duvelisib remain indeterminate. These results provide clinically relevant signals for sex-tailored AE surveillance and necessitate prospective validation.

PMID 42547343
阅读全文 →
PubMedWestern journal of nursing research2026-08-04

Cross-Cultural Validation and Psychometric Evaluation of the Birth Beliefs Scale Among Portuguese Pregnant Women.

Lopes Marlene M, Neves Teresa T, Vieira Margarida M, Cardoso Alexandrina A

Beliefs about childbirth shape women's expectations, decisions, and experiences. Although several tools assess related constructs such as fear or self-efficacy, few instruments focus specifically on childbirth beliefs. The Birth Beliefs Scale (BBS) addresses this gap by measuring 2 dimensions: beliefs in childbirth as a natural event and as a medical event. We sought to adapt the BBS to the Portuguese context and evaluate its psychometric properties. This methodological study involved cross-cultural adaptation and psychometric testing. The adaptation followed internationally recognized guidelines, including translation, synthesis, back-translation, expert review, and pretesting. Psychometric evaluation included exploratory and confirmatory factor analysis. The sample comprised 241 pregnant women enrolled in childbirth preparation programs in central Portugal. The original two-factor structure was partially confirmed following the removal of 3 items with low psychometric performance, including 2 related to labor pain. The Portuguese version (BBS-pt) demonstrated acceptable internal consistency for the Natural subscale (α = 0.68) and lower consistency for the Medical subscale (α = 0.58), suggesting cultural and contextual nuances in how birth beliefs are expressed. The BBS-pt is a promising instrument for assessing birth beliefs among Portuguese women. While further refinement is needed, particularly regarding pain-related items, the scale provides a valuable foundation for both research and clinical practice. It may assist nurse-midwives and other maternity care providers in tailoring antenatal education and intrapartum support to women's individual belief patterns, thereby contributing to more personalized and woman-centered care.

PMID 42549695
阅读全文 →
PubMedNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026-08-04

Comparative pharmacovigilance of Levodopa and Pramipexole: a disproportionality analysis of the FAERS database.

Hu Longtao L, Ren Yaolong Y, Li Yingchao Y, Cai Fangni F

This study aimed to comprehensively characterize and compare the safety profiles of Levodopa and Pramipexole, two cornerstone therapies for Parkinson's disease (PD), using real-world data from the FDA Adverse Event Reporting System (FAERS). A disproportionality analysis was conducted on FAERS data from Q1 2004 to Q2 2025. Reports listing Levodopa or Pramipexole as the 'primary suspect' drug were extracted and deduplicated. Four established algorithms (ROR, PRR, BCPNN, and EBGM) were employed for signal detection at both the System Organ Class (SOC) and Preferred Term (PT) levels. A sensitivity analysis excluding restless legs syndrome (RLS)-indicated Pramipexole reports was performed to assess indication bias. The analysis included 5,410 Levodopa and 6,894 Pramipexole reports. Distinct demographic and reporting patterns were observed. At the SOC level, Levodopa's strongest signal was in "Respiratory, thoracic and mediastinal disorders" (EBGM05 = 4.46), while Pramipexole's was in "Psychiatric disorders" (EBGM05 = 5.85). At the PT level, Levodopa was strongly associated with "Saliva discolouration" (EBGM05 = 769.94) and previously unhighlighted events like "Choking sensation" (EBGM05 = 71.68). Pramipexole showed extreme signals for "Restless legs augmentation syndrome" (EBGM05 = 1092.07) and "Gambling disorder" (EBGM05 = 610.24). A high frequency (31.47%) of Levodopa-associated events occurred within the first 30 days of treatment. The sensitivity analysis confirmed that Pramipexole's neuropsychiatric signals remained robust after excluding RLS-indicated reports. This large-scale study confirms the well-established risks of both drugs and identifies potential new safety signals for Levodopa, particularly concerning respiratory manifestations. The fundamentally distinct risk profiles underscore the necessity for drug-specific monitoring strategies and caution in combination therapy. These findings provide critical real-world evidence for optimizing risk-benefit management in PD.

PMID 42550252
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多PT-003